TITLE

Long-Term Efficacy and Safety of Linagliptinin Patients With Type 2 Diabetes and Severe Renal Impairment

AUTHOR(S)
MCGILL, JANET B.; SLOAN, LANCE; NEWMAN, JENNIFER; PATEL, SANJAY; SAUCE, CHRISTOPHE; VON EYNATTEN, MAXIMILIAN; WOERLE, HANS-JUERGEN
PUB. DATE
February 2013
SOURCE
Diabetes Care;Feb2013, Vol. 36 Issue 2, p237
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE--This placebo-controlled study assessed long-term efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes and severe renal impairment (RI). RESEARCH DESIGN AND METHODS--In this 1-year, double-blind study, 133 patients with type 2 diabetes (HbA1c 7.0-10.0%) and severe RI (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m²) at screening were randomized to linagliptin 5 mg (n = 68) or placebo (n = 65) once daily, added to existing background therapy. The primary efficacy end point was HbA1c change from baseline to week 12. Efficacy and safety end points were assessed after 1 year. RESULTS--At week 12, adjusted mean HbA1c decreased by -0.76% with linagliptin and 20.15% with placebo (treatment difference, -0.60%; 95% CI -0.89 to -0.31; P < 0.0001). HbA1c improvements were sustained with linagliptin (-0.71%) over placebo (0.01%) at 1 year (treatment difference -0.72%, -1.03 to -0.41; P < 0.0001). Mean insulin doses decreased by -6.2 units with linagliptin and -0.3 units with placebo. Overall adverse event incidence was similar over 1 year (94.1 vs. 92.3%). Incidence of severe hypoglycemia with linagliptin and placebo was comparably low (three patients per group). Linagliptin and placebo had little effect on renal function (median change in eGFR, -0.8 vs. -2.2 mL/min/1.73 m²), and no drug- related renal failure occurred. CONCLUSIONS--In patients with type 2 diabetes and severe RI, linagliptin provided clinically meaningful improvements in glycemic control with very low risk of severe hypoglycemia, stable body weight, and no cases of drug-related renal failure. The potential for linagliptin to spare insulin and provide long-term renal safety warrants further investigations.
ACCESSION #
85125679

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics